All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for UCB, INC. · Biopharmaceutical company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

Georgia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitor OECD negotiations related to Pillar II global minimum tax. Monitored H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. H.R.10431, the US Innovation and Global Competitiveness Act of 2026.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

Bills named in this filing 5

H.R. 1
One Big Beautiful Bill Act
H.R. 591
Defending American Jobs and Investment Act
H.R. 2423
Unfair Tax Prevention Act
H.R. 10431
U.S. Innovation and Global Competitiveness Act of 2026
S. 864
HELP Copays Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.